alexa From Viruses To Tumor Associated Antigen Cancer Vaccines
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Giulio Tarro
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
Abstract
A nti-HBV vaccine was found to prevent some liver tumors as well as anti-HPV vaccine is able to prevent most of the cervical cancers. Tumor associated antigens (TAA) were studied in SV40 and Polyoma viruses that were patterns for human cancer. Cancer immunotherapy, or the manipulation of the naturally occurring oncolytic immune reaction, is based on the observation that both in animals and humans neoplastic cell antigens stimulate the onset of specific humoral and cellular antibodies. Antigens, from autologous and homolougus human cancer cells, were obtained by various purification procedures. Tumor Liberated Protein (TLP) is a protein extracted from tumors and from cultured transformed cells. It is detectable in blood as well as in cancer tissue and behaves as a TAA of 50KD monomer, overexpressed in lung tumor and other epithelial adenocarcinomas. TLP is immunogenic in humans as evidenced by serum antibodies. The first observation demonstrated that when TLP is extracted from a tumor, purified in the laboratory, and reintroduced into the patient?s body, it boosts the immune system?s cancer responsive capabilities. TLP may have the potential to greatly improve the cure rate and/or serve as a cancer vaccine.
Biography
Giulio Tarro graduated from Medicine School, Naples University (1962). He is a Research Associate, Division of Virology and Cancer Research, Children?s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. He is also an Oncological Virology Professor, Naples University (1972-1985), Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). Since 2007, he is the Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor, Department of Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). He is the President Foundation de Beaumont Bonelli for Cancer Research.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords